c-Lecta, a global biotechnology company with technology leadership in the areas of enzyme engineering and bioprocess development for regulated markets such as the food and pharmaceutical industries, enters into a development partnership with the MDax-Company Symrise one. Founded in 2003 Symrise AG is one of the world's leading suppliers of fragrances and flavorings.
The focus of the cooperation is the development of an enzymatic process for the production of a flavoring substance. This strengthens c-LEcta's role as a partner to the food industry. “Cooperations of this kind with the aim of jointly developing and marketing new products are an important part of our corporate strategy. They enable us to build up future business and thus make an important contribution to our growth. We are very pleased about the new cooperation with Symrise," comments Dr. Marc Struhalla, CEO and co-founder of c-LEcta. There are currently seven active development cooperations with industry in the company. "This shows that c-LEcta is a sought-after partner for industry when it comes to competence and efficiency in the development of new biotechnological processes," Struhalla continues.
The second pillar of growth is our own product developments. c-LEcta develops and markets two categories of biotechnological products: industrial enzymes and biotechnologically manufactured ingredients. The c-LEcta enzyme products are used as process aids in industrial production. The aim is, for example, to make production processes more efficient or to make them possible in the first place. This allows products to be improved and resources to be conserved.
The ingredients products are low-molecular compounds that are very often of natural origin. They are buried as ingredients or additives in industrially manufactured products. With the help of c-LEcta's patented technology platform, such ingredients can be produced particularly efficiently and purely. By adding the ingredients, high-quality products for the food and pharmaceutical industries can be produced more cheaply.
At least two more product launches are planned for this year, expanding the portfolio for the target markets of the food and pharmaceutical industries. “Our well-stocked product pipeline, the wide range of possible applications for our products and global sales markets offer good prospects for long-term growth. The two pillars of our strategy, partnerships and our own products, complement each other so that we can optimally use and further develop our innovative technology platform," affirms Thomas Pfaadt, CFO of c-LEcta.
c-LEcta is a global biotechnology company with technology leadership in the areas of enzyme engineering and bioprocess development for regulated markets such as the food and pharmaceutical industries. The company, based in Leipzig, has established itself as a leading supplier of high-quality biotechnological products, be it in-house developments or in close cooperation with industry. c-LEcta currently employs more than 80 people.
c-LEcta delivers cost-efficient and sustainable production processes that open up new markets and enable better penetration of existing markets. The company excels at rapidly and efficiently developing best-in-class biotech solutions and successfully bringing to market and commercializing the resulting products. This allows c-LEcta to develop the unique potential of its core technologies. c-LEcta already has more than ten successfully marketed, high-quality, industrial biotech products.
Source: press release c-Lecta by 10.03.2020
The corona virus reached Saxony last week. The number of infections is also increasing in Bavaria. "According to the current risk assessment, we have to learn to live with this virus," says Dr. Nicole Porzig, deputy crisis manager in DRK Saxony. "Until an antidote is found, the population must be informed promptly and reliably," says Dr. Porzig further.
At the University Hospital Leipzig (UKL) and in the Sana Kliniken Leipziger Land, the electronically created medication plan "eMMa" was launched at the beginning of March - initially as a test operation under routine conditions. “eMMa” stands for “patient-centric e-medication management as an add-on to the medication plan”. Developed by medical IT specialists, doctors and pharmacists, the computer tool is intended to help optimize the process of admitting patients to the hospital. "eMMa" is a joint project funded by the Free State of Saxony and the EU.